A carregar...
Deletion Mutations Keep Kinase Inhibitors in the Loop
Effective clinical application of conformationally selective kinase inhibitors requires tailoring drug choice to the tumor's activating mutation(s). In this issue of Cancer Cell, Foster et al. (2016) describe how activating deletions in BRAF, EGFR, and HER2 cause primary resistance to common in...
Na minha lista:
| Publicado no: | Cancer Cell |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5028821/ https://ncbi.nlm.nih.gov/pubmed/27070691 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2016.03.017 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|